The single oral dose pharmacokinetics of carbamazepine-10,11-epoxide (CBZ-E), the active metabolite of carbamazepine, were studied in six healthy volunteers during a control session and during treatment with sodium valproate at a daily dose of 1000 mg. Sodium valproate increased the CBZ-E half-life from 6.3 ± 1.2 to 9.0 ± 2.0 h (Mean values ± S.D.) and decreased its clearance from 90.6 ± 18.8 to 63.2 ± 16.1 ml h-1 kg-1 (Mean values ± S.D.). These results suggest that sodium valproate impairs the elimination of CBZ-E, presumably by inhibiting its metabolism.
|Title of host publication||Bollettino - Lega Italiana contro l'Epilessia|
|Number of pages||2|
|Publication status||Published - 1989|
ASJC Scopus subject areas
- Clinical Neurology